These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18304628)

  • 1. Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.
    Riccioni R; Senese M; Diverio D; Riti V; Mariani G; Boe A; LoCoco F; Foà R; Peschle C; Sporn M; Testa U
    Leuk Res; 2008 Aug; 32(8):1244-58. PubMed ID: 18304628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide.
    Petronelli A; Saulle E; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Greggi S; Cognetti F; Russo MA; Sporn M; Testa U
    Cancer Lett; 2009 Sep; 282(2):214-28. PubMed ID: 19364626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.
    Konopleva M; Tsao T; Estrov Z; Lee RM; Wang RY; Jackson CE; McQueen T; Monaco G; Munsell M; Belmont J; Kantarjian H; Sporn MB; Andreeff M
    Cancer Res; 2004 Nov; 64(21):7927-35. PubMed ID: 15520199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
    Riccioni R; Senese M; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Lo-Coco F; Foà R; Peschle C; Testa U
    Br J Haematol; 2007 Oct; 139(2):194-205. PubMed ID: 17897295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer.
    Hyer ML; Shi R; Krajewska M; Meyer C; Lebedeva IV; Fisher PB; Reed JC
    Cancer Res; 2008 Apr; 68(8):2927-33. PubMed ID: 18413762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance.
    Ikeda T; Sporn M; Honda T; Gribble GW; Kufe D
    Cancer Res; 2003 Sep; 63(17):5551-8. PubMed ID: 14500394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.
    Ikeda T; Nakata Y; Kimura F; Sato K; Anderson K; Motoyoshi K; Sporn M; Kufe D
    Mol Cancer Ther; 2004 Jan; 3(1):39-45. PubMed ID: 14749474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to Fas/CD95 ligation in U937 cells is associated with multiple molecular mechanisms.
    Blomberg J; Ruuth K; Santos D; Lundgren E
    Anticancer Res; 2008; 28(2A):593-9. PubMed ID: 18506997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
    Tourneur L; Delluc S; Lévy V; Valensi F; Radford-Weiss I; Legrand O; Vargaftig J; Boix C; Macintyre EA; Varet B; Chiocchia G; Buzyn A
    Cancer Res; 2004 Nov; 64(21):8101-8. PubMed ID: 15520222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.
    Place AE; Suh N; Williams CR; Risingsong R; Honda T; Honda Y; Gribble GW; Leesnitzer LM; Stimmel JB; Willson TM; Rosen E; Sporn MB
    Clin Cancer Res; 2003 Jul; 9(7):2798-806. PubMed ID: 12855660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.
    Yates MS; Kwak MK; Egner PA; Groopman JD; Bodreddigari S; Sutter TR; Baumgartner KJ; Roebuck BD; Liby KT; Yore MM; Honda T; Gribble GW; Sporn MB; Kensler TW
    Cancer Res; 2006 Feb; 66(4):2488-94. PubMed ID: 16489057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
    Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
    Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDDO-Im is a stimulator of megakaryocytic differentiation.
    Petronelli A; Pelosi E; Santoro S; Saulle E; Cerio AM; Mariani G; Labbaye C; Testa U
    Leuk Res; 2011 Apr; 35(4):534-44. PubMed ID: 21035854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bid is cleaved upstream of caspase-8 activation during TRAIL-mediated apoptosis in human osteosarcoma cells.
    Garnett TO; Filippova M; Duerksen-Hughes PJ
    Apoptosis; 2007 Jul; 12(7):1299-315. PubMed ID: 17431792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.
    Liby K; Voong N; Williams CR; Risingsong R; Royce DB; Honda T; Gribble GW; Sporn MB; Letterio JJ
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4288-93. PubMed ID: 16857804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.
    Suh WS; Kim YS; Schimmer AD; Kitada S; Minden M; Andreeff M; Suh N; Sporn M; Reed JC
    Leukemia; 2003 Nov; 17(11):2122-9. PubMed ID: 12931220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
    Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F
    Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.